441 related articles for article (PubMed ID: 24527451)
21. Freezing of gait in early Parkinson's disease: Nigral iron content estimated from magnetic resonance imaging.
Wieler M; Gee M; Camicioli R; Martin WR
J Neurol Sci; 2016 Feb; 361():87-91. PubMed ID: 26810522
[TBL] [Abstract][Full Text] [Related]
22. Nigral iron deposition in common tremor disorders.
Homayoon N; Pirpamer L; Franthal S; Katschnig-Winter P; Kögl M; Seiler S; Wenzel K; Hofer E; Deutschmann H; Fazekas F; Langkammer C; Ropele S; Schmidt R; Schwingenschuh P
Mov Disord; 2019 Jan; 34(1):129-132. PubMed ID: 30536988
[TBL] [Abstract][Full Text] [Related]
23. Is iron involved in pathogenesis of Parkinson's disease--Mössbauer spectroscopy study of substantia nigra in control and disease brains.
Friedman A; Bauminger ER; Gałazka-Friedman J; Barcikowska M; Hechel D; Nowik I; Marczewska M
Neurol Neurochir Pol; 1996; 30 Suppl 2():95-103. PubMed ID: 9100247
[No Abstract] [Full Text] [Related]
24. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
Gu M; Owen AD; Toffa SE; Cooper JM; Dexter DT; Jenner P; Marsden CD; Schapira AH
J Neurol Sci; 1998 Jun; 158(1):24-9. PubMed ID: 9667773
[TBL] [Abstract][Full Text] [Related]
26. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
Kastner A; Hirsch EC; Lejeune O; Javoy-Agid F; Rascol O; Agid Y
J Neurochem; 1992 Sep; 59(3):1080-9. PubMed ID: 1494900
[TBL] [Abstract][Full Text] [Related]
27. Effect of deep brain stimulation on substantia nigra neurons in a rat model of Parkinson's disease.
Wu ST; Ma Y; Zhang K; Zhang JG
Chin Med J (Engl); 2012 Nov; 125(22):4072-5. PubMed ID: 23158145
[TBL] [Abstract][Full Text] [Related]
28. Altered proteasomal function in sporadic Parkinson's disease.
McNaught KS; Belizaire R; Isacson O; Jenner P; Olanow CW
Exp Neurol; 2003 Jan; 179(1):38-46. PubMed ID: 12504866
[TBL] [Abstract][Full Text] [Related]
29. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
[TBL] [Abstract][Full Text] [Related]
30. Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.
Guan X; Xu X; Zhang M
Neurosci Bull; 2017 Oct; 33(5):561-567. PubMed ID: 28516282
[TBL] [Abstract][Full Text] [Related]
31. In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism.
Lobb CJ; Zaheer AK; Smith Y; Jaeger D
J Neurophysiol; 2013 Dec; 110(12):2792-805. PubMed ID: 24068758
[TBL] [Abstract][Full Text] [Related]
32. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study.
Oestreicher E; Sengstock GJ; Riederer P; Olanow CW; Dunn AJ; Arendash GW
Brain Res; 1994 Oct; 660(1):8-18. PubMed ID: 7828004
[TBL] [Abstract][Full Text] [Related]
33. Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits.
Schuff N; Wu IW; Buckley S; Foster ED; Coffey CS; Gitelman DR; Mendick S; Seibyl J; Simuni T; Zhang Y; Jankovic J; Hunter C; Tanner CM; Rees L; Factor S; Berg D; Wurster I; Gauss K; Sprenger F; Seppi K; Poewe W; Mollenhauer B; Knake S; Mari Z; McCoy A; Ranola M; Marek K
Mov Disord; 2015 Dec; 30(14):1885-92. PubMed ID: 26260437
[TBL] [Abstract][Full Text] [Related]
34. Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson's Disease on Brain Networks.
Wen J; Guo T; Wu J; Bai X; Zhou C; Wu H; Liu X; Chen J; Cao Z; Gu L; Pu J; Zhang B; Zhang M; Guan X; Xu X
J Parkinsons Dis; 2022; 12(8):2479-2492. PubMed ID: 36336939
[TBL] [Abstract][Full Text] [Related]
35. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
Wang C; Fan G; Xu K; Wang S
Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
[TBL] [Abstract][Full Text] [Related]
36. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
[TBL] [Abstract][Full Text] [Related]
37. The progression of Parkinson disease: a hypothesis.
Lang AE
Neurology; 2007 Mar; 68(12):948-52. PubMed ID: 17372132
[TBL] [Abstract][Full Text] [Related]
38. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease.
Shashidharan P; Good PF; Hsu A; Perl DP; Brin MF; Olanow CW
Brain Res; 2000 Sep; 877(2):379-81. PubMed ID: 10986355
[TBL] [Abstract][Full Text] [Related]
39. Genetics of iron regulation and the possible role of iron in Parkinson's disease.
Rhodes SL; Ritz B
Neurobiol Dis; 2008 Nov; 32(2):183-95. PubMed ID: 18675357
[TBL] [Abstract][Full Text] [Related]
40. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits.
Zhang J; Stanton DM; Nguyen XV; Liu M; Zhang Z; Gash D; Bing G
Neuroscience; 2005; 135(3):829-38. PubMed ID: 16165292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
